Multiple Sclerosis, Chronic Progressive  >>  Rituxan (rituximab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rituxan (rituximab) / Roche
NCT01212094: Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

Terminated
1/2
44
US
Rituximab, normal saline, saline
National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
12/15
12/15

Download Options